Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19766818 | 0.93 | HSP90AB1 (0.40) | HSP90AB1HSP90AA1BRD4TRAP1 | |
| SCHEMBL19650242 | 0.91 | BRD4 (0.42) | BRD4 | |
| SCHEMBL20427916 | 0.91 | ALDH1A1 (0.40) | HSP90AB1HSP90AA1BRD4RXRA | |
| SCHEMBL20427884 | 0.91 | MEN1 (0.39) | BRD4RXRA | |
| SCHEMBL19650370 | 0.90 | BRD4 (0.44) | BRD4 | |
| SCHEMBL19638242 | 0.89 | RXRA (0.41) | BRD4RXRA | |
| SCHEMBL19638463 | 0.87 | GLRA1 (0.39) | BRD4RXRA | |
| SCHEMBL19650369 | 0.87 | GLRA1 (0.46) | BRD4RXRA | |
| SCHEMBL2349903 | 0.85 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1 | |
| SCHEMBL17948632 | 0.85 | HSP90AB1 (0.40) | HSP90AB1HSP90AA1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851071-B2 | M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-12-01 | — | — | US | disclosed |
| US-10851071-B2 | M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20190284146-A1 | M-DIHYDROXYBENZENE DERIVATIVE CRYSTAL AND SALT, AND MANUFACTURING METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| US-20190284146-A1 | M-DIHYDROXYBENZENE DERIVATIVE CRYSTAL AND SALT, AND MANUFACTURING METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284146-A1 | M-DIHYDROXYBENZENE DERIVATIVE CRYSTAL AND SALT, AND MANUFACTURING METHOD THEREOF | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885BRD4 856/4885 |
| US-10851071-B2 | M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885BRD4 856/4885 |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885BRD4 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.